Screening of referrals for the mutations associated with the fragile X syndrome constitutes a significant workload in many genetics laboratories. Since the great majority of these referrals will be negative, there is a need for a rapid and inexpensive screening test. We have developed an assay which allows simultaneous amplification of the triplet repeat sequences at the FRAXA and FRAXE loci by polymerase chain reaction, and detection of the products on non-denaturing gels stained with ethidium bromide. Alleles of normal size are detected, leaving a small minority of samples to be tested by Southern blotting. A PCR based assay for detection ofmethylation at the CpG island upstream of the FMR-1 gene has also been devised.
The fragile X syndrome is the most common inherited cause of mental retardation, affecting approximately 1/1250 males and 1/2000 females. ' Direct analysis of the CGG expansion mutation by Southern blotting has begun to replace cytogenetic analysis for the laboratory diagnosis of the fragile X syndrome." However, blotting is a relatively expensive and labour intensive procedure, particularly in the context of screening routine referrals for the fragile X syndrome, the great majority of which will be negative. We therefore developed a two stage protocol'2 in which samples are first screened for the presence of a normal allele by amplification across the CGG repeat using the polymerase chain reaction.'3 Males in whom an allele of normal size is detected, and females in whom two normal alleles are detected, can be scored as unaffected, and the few remaining samples then analysed by Southern blotting.
Current methods for PCR analysis of the FRAXA mutation involve the use of 32P to label the PCR product,'3 or blotting of the products onto a membrane and hybridisation with a biotinylated probe. 4 Furthermore, the fact that up to 10% of cytogenetically diagnosed fragile X positive cases have the FRAXE mutation2 15 suggests that this mutation should also be tested for in routine referrals. We have therefore developed a rapid, non-radioactive PCR method which screens for both the FRAXA and FRAXE mutations simultaneously. Males who do not have an expansion mutation at either of these loci are identified by the presence of FRAXA and FRAXE alleles of normal size on non-denaturing gels stained with ethidium bromide. The majority of females who do not have an expansion at the FRAXA locus can also be identified, since about two-thirds of females are heterozygous for the polymorphic CGG repeat,'3 14 and two alleles of normal size will be detected on the gel. We have also devised a PCR based assay to detect methylation of the CpG island upstream of the FMR-1 gene, since this might provide confirmation of the presence ofan expanded FRAXA allele in affected males. The presence of a high G + C content in the target DNA template presents difficulties for in vitro DNA amplification across CG rich triplet repeats. In our experiments the G + C content in the FRAXA fragment was between 81% (two CGG repeats) and 93% (52 CGG repeats). The incorporation of C7dGTP to destabilise secondary DNA structure allows successful amplification of CG rich segments,'8 which led to the use of a 3:1 ratio of C7dGTP: dGTP in the original FRAXA PCR test. 13 However, since PCR products with a high content of C7dGTP do not stain efficiently with ethidium bromide,'9 current methods for detecting the amplified fragment involve radioisotope labelling'3 or blotting" and detection with biotinylated or chemically modified nucleotides. 14 Several different ratios of C7dGTP:dGTP were tested, and a ratio of 1:3 was found to allow amplification of FRAXE and FRAXA alleles within the normal range, and efficient staining of the PCR products with ethidium bromide. The largest FRAXA allele amplified with this protocol contained 53 repeats, whereas alleles of 62 repeats (as measured by a radioactive PCR assay and sized on a sequencing gel'2) or more failed to amplify. Resolution of one repeat unit differences at the FRAXA locus on a 20cm 10% polyacrylamide gel using primers directly adjacent to the CGG repeat. The samples in lanes 1 and 4 are from females who are homozygous on the sequencing gel assay; those in lanes 2, 5, and 6 differ by one repeat unit; and the sample in lane 3 has alleles which differ by several repeats.
ations at either of these loci can readily be identified by electrophoresis of the PCR products on a minigel ( fig 1A, lanes 1-5) [6] [7] [8] can also be scored as normal for FRAXA, since an allele with a premutation or a full mutation will not be amplified (with the exception of a deletion at the FRAXE locus, see below). The heterozygosity rate for females is only about 20% with the resolving power of the minigel which was used to screen male samples. However, the shorter FRAXA PCR product generated in our assay had the additional advantage that alleles which differed by only one repeat unit could be resolved on a 20 cm non-denaturing 10% polyacrylamide gel. Lanes 1 and 4 in fig 1 B are products from females previously shown to be homozygous for a normal allele by PCR analysis on a denaturing gel and Southern blotting, and samples in lanes 2, 5, and 6 had alleles which differed by one repeat unit. Also, the residue of the PCR products from the amplification for the minigel can be used for the larger gel, so the PCR does not have to be repeated. We have tested 178 normal females and found 66% to be heterozygous. This is comparable with other reported rates of 63%"3 and 80%.14 The size of the FRAXE PCR product using the published primers9 is too large to resolve alleles which differ by less than three to four repeats.
About 80% of routine referrals to our Genetics Centre for fragile X testing are from male patients, and 3% of all samples are positive." An average of 77 to 78 males out of 100 samples will therefore be scored as normal for both FRAXA and FRAXE on the minigel, and three to four females will be heterozygous for normal FRAXA alleles. A further nine to ten females will be shown to be heterozygous for FRAXA on the 20 cm gel. Thus about 90% of routine referrals can be eliminated from testing by Southern blotting with the PCR assay, with the limitation that female carriers of FRAXE mutations will not be identified. A false negative diagnosis would be obtained in an affected male who was a mosaic for a normal allele and a full mutation. However, no 2 and 3) .
expanded allele in affected males by Southern blot analysis should, however, always be carried out if facilities for radioactive analysis are available, and is essential for the diagnosis of female 2, lanes 5-6). This was expected, since the alleles would be fully methylated and thus not digested by the enzyme. We did not expect to obtain a product in normal males, since the site would be unmethylated and hence fully cleaved by the enzyme (fig 2, lanes 1 and 4) . However, a weak signal was observed in the digested track from some normal males (lanes 2 and 3), at a level of about 5 to 10% of that observed in the undigested track. We attempted to exclude partial digestion as the cause of this by re-extraction of samples with phenolchloroform, and by digestion with a large excess of either BstZI or EagI, but the weak signal in some samples was retained. BshHlI, which has two methylated sites within the amplified region, provides better discrimination. We conclude that either some molecules are resistant to digestion because of secondary structure of the DNA in this region, or that a small proportion of FMR-1 genes with normal CGG alleles are methylated. The fact that methylated normal alleles have not been observed by Southern blotting could be explained by the lower sensitivity of the blotting technique.
The methylation assay was tested for its ability to detect affected FRAXA males in a blind test of 40 coded samples which included 20 normal and 20 affected males. All samples were correctly identified, as compared with results obtained by Southern blotting. The fact that a low level of amplification was seen in digested DNA from some normal males suggests that particular care should be exercised in the interpretation of the results of this assay. We have observed this in a total of 13 out of 52 (25%) normal males tested with the assay, and although all were clearly distinguishable from the equivalent signals observed in digested and undigested DNA from affected males, we suggest that extensive blind testing should be carried out in individual laboratories before using the assay for diagnostic purposes.
In conclusion, the non-radioactive PCR assay that we have described appears to be a reliable, cheap, and efficient test for initial screening of samples for the presence of carriers.
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